“The Doctor Says You Cannot Have [Buprenorphine]” Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine

References

• Allen, B., & Harocopos, A. (2016). Non-prescribed buprenorphine in New York City: Motivations for use, practices of diversion, and experiences of stigma. Journal of Substance Abuse Treatment, 70, 81–86. https://doi.org/10.1016/j.jsat.2016.08.002
   PubMed Web of Science ®Google Scholar
• Auerbach, C., & Silverstein, L. B. (2003). Qualitative data: An introduction to coding and analysis (Vol. 21). NYU press.
   Google Scholar
• Bachhuber, M. A., Thompson, C., Prybylowski, A., Benitez, J. M. S. W., Mazzella, S. M. A., & Barclay, D. (2018). Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Substance Abuse, 39(2), 167–172. https://doi.org/10.1080/08897077.2018.1443541
   PubMed Web of Science ®Google Scholar
• Bazazi, A. R., Yokell, M., Fu, J. J., Rich, J. D., & Zaller, N. D. (2011). Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine, 5(3), 175–180. https://doi.org/10.1097/ADM.0b013e3182034e31
   PubMed Web of Science ®Google Scholar
• Biernacki, P. (1990). Recovery from opiate addiction without treatment: A summary. NIDA Research Monograph, 98, 113–119.
   PubMedGoogle Scholar
• Carroll, J. J., Rich, J. D., & Green, T. C. (2018). The more things change: Buprenorphine/naloxone diversion continues while treatment remains inaccessible. Journal of Addiction Medicine, 12(6), 459–465. https://doi.org/10.1097/ADM.0000000000000436
   PubMed Web of Science ®Google Scholar
• Carter, J., Zevin, B., & Lum, P. J. (2019). Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addiction Science & Clinical Practice, 14(1), 20. https://doi.org/10.1186/s13722-019-0149-1
   PubMedGoogle Scholar
• Chilcoat, H. D., Amick, H. R., Sherwood, M. R., & Dunn, K. E. (2019). Buprenorphine in the United States: Motives for abuse, misuse, and diversion. Journal of Substance Abuse Treatment, 104, 148–157. https://doi.org/10.1016/j.jsat.2019.07.005
   PubMed Web of Science ®Google Scholar
• Cicero, T. J., Ellis, M. S., & Chilcoat, H. D. (2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117–123. https://doi.org/10.1016/j.drugalcdep.2018.09.007
   PubMed Web of Science ®Google Scholar
• Cunningham, C. O., Roose, R. J., Starrels, J. L., Giovanniello, A., & Sohler, N. L. (2013). Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes. Journal of Addiction Medicine, 7(4), 287–293. https://doi.org/10.1097/ADM.0b013e31829727b2
   PubMed Web of Science ®Google Scholar
• Dean, A. J., Saunders, J. B., & Bell, J. (2011). Heroin use, dependence, and attitudes to treatment in non-treatment-seeking heroin users: A pilot study. Substance Use & Misuse, 46(4), 417–425. https://doi.org/10.3109/10826084.2010.501655
   PubMed Web of Science ®Google Scholar
• Duncan, L. G., Mendoza, S., & Hansen, H. (2015). Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science, 1(2), 31–36. https://doi.org/10.17352/2455-3484.000008
   PubMedGoogle Scholar
• Fox, A. D., Chamberlain, A., Frost, T., & Cunningham, C. O. (2015). Harm reduction agencies as a potential site for buprenorphine treatment. Substance Abuse, 36(2), 155–160. https://doi.org/10.1080/08897077.2015.1011820
   PubMed Web of Science ®Google Scholar
• Genberg, B. L., Gillespie, M., Schuster, C. R., Johanson, C.-E., Astemborski, J., Kirk, G. D., Vlahov, D., & Mehta, S. H. (2013). Prevalence and correlates of street-obtained buprenorphine use among current and former injectors in Baltimore, Maryland. Addictive Behaviors, 38(12), 2868–2873. https://doi.org/10.1016/j.addbeh.2013.08.008
   PubMed Web of Science ®Google Scholar
• Granfield, R., & Cloud, W. (2001). Social context and “natural recovery”: The role of social capital in the resolution of drug-associated problems. Substance Use & Misuse, 36(11), 1543–1570. https://doi.org/10.1081/ja-100106963
   PubMed Web of Science ®Google Scholar
• Gwin Mitchell, S., Kelly, S. M., Brown, B. S., Schacht Reisinger, H., Peterson, J. A., Ruhf, A., Agar, M. H., O’Grady, K. E., & Schwartz, R. P. (2009). Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. American Journal on Addictions, 18(5), 346–355. https://doi.org/10.3109/10550490903077820
   PubMed Web of Science ®Google Scholar
• Hewell, V. M., Vasquez, A. R., & Rivkin, I. D. (2017). Systemic and individual factors in the buprenorphine treatment-seeking process: A qualitative study. Substance Abuse Treatment, Prevention, and Policy, 12(1), 3https://doi.org/https://doi.org/10.1186/s13011-016-0085-y
   PubMed Web of Science ®Google Scholar
• Holcomb, S., Mosse, D., Oliphant-Wells, T., & Shim, M. M. (2020). Engaging an unstably housed population with low-barrier buprenorphine treatment at a syringe services program: Lessons learned from Seattle, Washington. Subst Abus, 41(3), 356–364. https://doi.org/10.1080/08897077.2019.1635557 
   Google Scholar
• Iserson, K. V. (1999). Principles of biomedical ethics. Emergency Medicine Clinics of North America, 17(2), 283–306. https://doi.org/10.1016/S0733-8627(05)70060-2
   PubMed Web of Science ®Google Scholar
• Jakubowski, A., & Fox, A. (2020). Defining Low-threshold Buprenorphine Treatment. J Addict Med, 14(2), 95–98. https://doi.org/10.1097/adm.0000000000000555
   Google Scholar
• Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015). National and state treatment need and capacity for opioid agonist medication-assisted treatment. American Journal of Public Health, 105(8), e55–e63. https://doi.org/10.2105/AJPH.2015.302664
   PubMed Web of Science ®Google Scholar
• Joosten, E. A., de Jong, C. A., de Weert-van Oene, G. H., Sensky, T., & van der Staak, C. P. (2009). Shared decision-making reduces drug use and psychiatric severity in substance-dependent patients. Psychotherapy and Psychosomatics, 78(4), 245–253. https://doi.org/10.1159/000219524
   PubMed Web of Science ®Google Scholar
• Joosten, E. A., De Jong, C. A., de Weert-van Oene, G. H., Sensky, T., & van der Staak, C. P. (2011). Shared decision-making: Increases autonomy in substance-dependent patients. Substance Use & Misuse, 46(8), 1037–1038. https://doi.org/10.3109/10826084.2011.552931
   PubMed Web of Science ®Google Scholar
• Kinsella, M. (2017). Fostering client autonomy in addiction rehabilitative practice: The role of therapeutic “presence. Journal of Theoretical and Philosophical Psychology, 37(2), 91–108. https://doi.org/10.1037/teo0000056
   Web of Science ®Google Scholar
• Kourounis, G., Richards, B. D. W., Kyprianou, E., Symeonidou, E., Malliori, M.-M., & Samartzis, L. (2016). Opioid substitution therapy: Lowering the treatment thresholds. Drug and Alcohol Dependence, 161, 1–8. https://doi.org/10.1016/j.drugalcdep.2015.12.021
   PubMed Web of Science ®Google Scholar
• LaBelle, C. T., Bergeron, L. P., Wason, K. W., & Ventura, A. S. (2018). Clinical guidelines for the office based addiction treatment program for the use of buprenorphine and naltrexone forumlations in the treatment of substance use disorder. https://www.bmcobat.org/resources/?category=1
   Google Scholar
• Lagisetty, P. A., Ross, R., Bohnert, A., Clay, M., & Maust, D. T. (2019). Buprenorphine Treatment Divide by Race/Ethnicity and Payment. JAMA Psychiatry, 76(9), 979–981. https://doi.org/10.1001/jamapsychiatry.2019.0876
   PubMed Web of Science ®Google Scholar
• Lofwall, M. R., & Walsh, S. L. (2014). A review of buprenorphine diversion and misuse: The current evidence base and experiences from around the world. Journal of Addiction Medicine, 8(5), 315–326. https://doi.org/10.1097/ADM.0000000000000045
   PubMed Web of Science ®Google Scholar
• Marchand, K., Beaumont, S., Westfall, J., MacDonald, S., Harrison, S., Marsh, D. C., Schechter, M. T., & Oviedo-Joekes, E. (2019). Conceptualizing patient-centered care for substance use disorder treatment: Findings from a systematic scoping review. Substance Abuse Treatment, Prevention, and Policy, 14(1), 37.https://doi.org/10.1186/s13011-019-0227-0
   PubMed Web of Science ®Google Scholar
• Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018). The next stage of buprenorphine care for opioid use disorder. Annals of Internal Medicine, 169(9), 628–635. https://doi.org/10.7326/M18-1652
   PubMed Web of Science ®Google Scholar
• McCormick, C. G. (2002). Subutex and Suboxone Approval Letter. Food and Drug Administration. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/20732,20733ltr.pdf.
   Google Scholar
• McLean, K., & Kavanaugh, P. R. (2019). “They’re making it so hard for people to get help:” Motivations for non-prescribed buprenorphine use in a time of treatment expansion . The International Journal on Drug Policy, 71, 118–124. https://doi.org/10.1016/j.drugpo.2019.06.019
   PubMed Web of Science ®Google Scholar
• Mitchell, S. G., Kelly, S. M., Brown, B. S., Reisinger, H. S., Peterson, J. A., Ruhf, A., Agar, M. H., & Schwartz, R. P. (2009). Incarceration and opioid withdrawal: The experiences of methadone patients and out-of-treatment heroin users. Journal of Psychoactive Drugs, 41(2), 145–152. https://doi.org/10.1080/02791072.2009.10399907
   PubMed Web of Science ®Google Scholar
• Rhee, T. G., & Rosenheck, R. A. (2019). Buprenorphine prescribing for opioid use disorder in medical practices: Can office-based out-patient care address the opiate crisis in the United States?Addiction, 114(11), 1992–1999. https://doi.org/10.1111/add.14733
   PubMed Web of Science ®Google Scholar
• Ross, L. E., Vigod, S., Wishart, J., Waese, M., Spence, J. D., Oliver, J., Chambers, J., Anderson, S., & Shields, R. (2015). Barriers and facilitators to primary care for people with mental health and/or substance use issues: A qualitative study. BMC Family Practice, 16(1), 135. https://doi.org/10.1186/s12875-015-0353-3
   PubMedGoogle Scholar
• Silverstein, S. M., Daniulaityte, R., Martins, S. S., Miller, S. C., & Carlson, R. G. (2019). “Everything is not right anymore”: Buprenorphine experiences in an era of illicit fentanyl. The International Journal on Drug Policy, 74, 76–83. https://doi.org/10.1016/j.drugpo.2019.09.003
   PubMed Web of Science ®Google Scholar
• Silverstein, S. M., Daniulaityte, R., Miller, S. C., Martins, S. S., & Carlson, R. G. (2020). On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug and Alcohol Dependence, 210, 107958. https://doi.org/10.1016/j.drugalcdep.2020.107958
   PubMed Web of Science ®Google Scholar
• Stancliff, S., Joseph, H., Fong, C., Furst, T., Comer, S. D., & Roux, P. (2012). Opioid maintenance treatment as a harm reduction tool for opioid-dependent individuals in New York City: the need to expand access to buprenorphine/naloxone in marginalized populations. Journal of Addictive Diseases, 31(3), 278–287. https://doi.org/10.1080/10550887.2012.694603
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. (2020). Medications for opioid use disorder: A treatment improvement protocol (TIP) 63 (TIP Series, Issue. https://store.samhsa.gov/product/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document/PEP20-02-01-006
   Google Scholar
• Sullivan, M. A., Birkmayer, F., Boyarsky, B. K., Frances, R. J., Fromson, J. A., Galanter, M., Levin, F. R., Lewis, C., Nace, E. P., Suchinsky, R. T., Tamerin, J. S., Tolliver, B., & Westermeyer, J. (2008). Uses of coercion in addiction treatment: Clinical aspects. The American Journal on Addictions, 17(1), 36–47. https://doi.org/10.1080/10550490701756369
   PubMed Web of Science ®Google Scholar
• Tsogia, D., Copello, A., & Orford, J. (2001). Entering treatment for substance misuse: A review of the literature. Journal of Mental Health, 10(5), 481–499. https://doi.org/10.1080/09638230126722
   Google Scholar
• Vearrier, L. (2019). The value of harm reduction for injection drug use: A clinical and public health ethics analysis. Disease-a-Month: DM, 65(5), 119–141. https://doi.org/10.1016/j.disamonth.2018.12.002
   PubMed Web of Science ®Google Scholar